HIV drug fails to prove COVID-19 prevention in abandoned trial
NCT ID NCT04405271
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether a daily pill used for HIV (TAF/FTC) could prevent COVID-19 in healthcare workers at high risk of exposure. Over 1,300 workers were randomly assigned to get the drug or a placebo for 12 weeks. The trial was stopped early, so it's unclear if the drug had any real benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Emtricitabine/Tenofovir Alafenamide (FTC/TAF) oral tablet
What this could lead to
If it had worked, this could have pointed toward a new way to prevent COVID-19 in high-risk workers using an existing HIV drug.
What could go wrong
The trial was terminated early, so we don't have clear evidence it works. Also, this drug is normally for HIV, and its effectiveness against COVID-19 was uncertain from the start.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sociedad Argentina de Infectología, A. J. Carranza 974
Buenos Aires, Buenos Aires F.D., C1085, Argentina